Corcept Therapeutics (CORT) Cash Flow Statement

Click line-items for a historical chart and %

Operating activities
Net loss	3.54M
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization of property and equipment	72K
Expense related to stock options, net of reversals	5.1M
Expense related to stock issued for services or in conjunction with license agreement
Expense related to stock issued below fair value
Interest accrued on convertible promissory note
Settlement of liquidated damages in stock
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	-679K
Other assets	0
Accounts payable	2.98M
Accrued clinical expenses
Other liabilities
Net cash used in operating activities
Investing activities
Purchases of property and equipment	-119K
Purchases of investments
Maturities of investments
Net cash used in investing activities
Financing activities
Proceeds from issuance of common stock and warrants, including collection of notes receivable, net of issuance costs
Proceeds from issuance of convertible preferred stock, net of cash paid for issuance costs
Proceeds from issuance of convertible notes
Principal payments of obligations under capital leases
Net cash provided by financing activities
Net increase in cash and cash equivalents	7.43M
Cash and cash equivalents, at beginning of period	40.44M
Cash and cash equivalents, at end of period	47.87M

Entities mentioned with CORT